Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
Immune evasion is essential for carcinogenesis and cancer progression. Programmed death-ligand 1 (PD-L1), a critical immune checkpoint molecule, interacts with programmed death receptor-1 (PD-1) on immune cells to suppress anti-tumor immune responses. In the past decade, antibodies targeting PD-1/PD...
Main Authors: | Yao Jiang, Kai Hong, Yingchao Zhao, Kai Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1228200/full |
Similar Items
-
Programmed Death Ligand 1 Regulatory Crosstalk with Ubiquitination and Deubiquitination: Implications in Cancer Immunotherapy
by: Soon-Bin Kim, et al.
Published: (2024-03-01) -
Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
by: Peng Ding, et al.
Published: (2023-05-01) -
Regulation of Deubiquitinating Enzymes by Post-Translational Modifications
by: Tanuza Das, et al.
Published: (2020-06-01) -
Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity
by: Xing Huang, et al.
Published: (2020-08-01) -
Ubiquitination and Deubiquitination in Oral Disease
by: Sachio Tsuchida, et al.
Published: (2021-05-01)